Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Rajesh, Kaldate"'
Autor:
Richard D. Press, Dana Dressel, Michelle McBean, Ing S. Tiong, Matthew W. Anderson, David Pride, Aarthi Raman, Rachelle R. Doom, Rajesh Kaldate
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 14, p 7912 (2024)
Quantitative assessment of nucleophosmin 1 (NPM1) mutation status is integral to evaluating measurable residual disease (MRD) in NPM1-mutated acute myeloid leukemia (AML) patients. In a retrospective study, leftover peripheral blood (PB) specimens (n
Externí odkaz:
https://doaj.org/article/4dd1898962874dd1827d41c9a1ba1c9e
Autor:
Thomas Powles, Toni K. Choueiri, Robert J. Motzer, Eric Jonasch, Sumanta Pal, Nizar M. Tannir, Sabina Signoretti, Rajesh Kaldate, Christian Scheffold, Evelyn Wang, Dana T. Aftab, Bernard Escudier, Daniel J. George
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS) and overall survival (OS) versus everolimus in patients with advanced RCC after prior antiangiogenic therapy. Methods In this exploratory analysis,
Externí odkaz:
https://doaj.org/article/08953196fa7443bbb663ea7061737037
Autor:
Thomas Powles, Toni K. Choueiri, Robert J. Motzer, Eric Jonasch, Sumanta Pal, Nizar M. Tannir, Sabina Signoretti, Rajesh Kaldate, Christian Scheffold, Evelyn Wang, Dana T. Aftab, Bernard Escudier, Daniel J. George
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-2 (2021)
Externí odkaz:
https://doaj.org/article/fb97b853f0ab49559f8e621718cfb4a1
Autor:
Ghassan K. Abou-Alfa, Anthony B. El-Khoueiry, Ann-Lii Cheng, Rajesh Kaldate, David W. Markby, Vincenzo Dadduzio, Albert Tran, Vincent C. Tam, Jean-Frederic Blanc, Stephen L. Chan, Thomas Yau, Joong-Won Park, Philippe Merle, Lorenza Rimassa, Tim Meyer, Robin Kate Kelley
Purpose:The phase III CELESTIAL study demonstrated improved overall survival (OS) and progression-free survival (PFS) with cabozantinib versus placebo in patients with previously treated, advanced hepatocellular carcinoma (HCC). We analyzed outcomes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52683f429b0442e18b5c2c784e1943d2
https://doi.org/10.1158/1078-0432.c.6529197
https://doi.org/10.1158/1078-0432.c.6529197
Autor:
Ghassan K. Abou-Alfa, Anthony B. El-Khoueiry, Ann-Lii Cheng, Rajesh Kaldate, David W. Markby, Vincenzo Dadduzio, Albert Tran, Vincent C. Tam, Jean-Frederic Blanc, Stephen L. Chan, Thomas Yau, Joong-Won Park, Philippe Merle, Lorenza Rimassa, Tim Meyer, Robin Kate Kelley
Supplementary Data_Clean File
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1221a1d53068b1cc61d3e76c8e03eaf8
https://doi.org/10.1158/1078-0432.22475850.v1
https://doi.org/10.1158/1078-0432.22475850.v1
Autor:
Ghassan K. Abou-Alfa, Anthony B. El-Khoueiry, Ann-Lii Cheng, Rajesh Kaldate, David W. Markby, Vincenzo Dadduzio, Albert Tran, Vincent C. Tam, Jean-Frederic Blanc, Stephen L. Chan, Thomas Yau, Joong-Won Park, Philippe Merle, Lorenza Rimassa, Tim Meyer, Robin Kate Kelley
Figure S3. AFP response cutoff determination for overall survival by maximally selected rank statistics. Cutpoint determination plots showing (A) histogram distribution and (B) rank statistic plot of percent AFP change from baseline at Week 8 for pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e00a9b1fc02271dccf307a495695b185
https://doi.org/10.1158/1078-0432.22475856
https://doi.org/10.1158/1078-0432.22475856
Autor:
Rajesh Kaldate, Eric Jonasch, Robert J. Motzer, Bernard Escudier, Sabina Signoretti, Sumanta K. Pal, Thomas Powles, E. Wang, Toni K. Choueiri, Daniel J. George, Dana T. Aftab, Christian Scheffold, Nizar M. Tannir
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Background In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS) and overall survival (OS) versus everolimus in patients with advanced RCC after prior antiangiogenic therapy. Methods In this exploratory analysis, plasma b
Autor:
David W. Markby, Rajesh Kaldate, Robin Kate Kelley, Joong-Won Park, Ghassan K. Abou-Alfa, Vincent C. Tam, Anthony B. El-Khoueiry, Philippe Merle, Thomas Yau, Stephen L. Chan, Ann-Lii Cheng, Lorenza Rimassa, Vincenzo Dadduzio, Jean-Frédéric Blanc, Tim Meyer, Albert Tran
Publikováno v:
Clin Cancer Res
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 26, iss 18
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 26, iss 18
Purpose: The phase III CELESTIAL study demonstrated improved overall survival (OS) and progression-free survival (PFS) with cabozantinib versus placebo in patients with previously treated, advanced hepatocellular carcinoma (HCC). We analyzed outcomes
Autor:
Thomas Yau, Lorenza Rimassa, Rajesh Kaldate, JW Park, Ghassan K. Abou-Alfa, V Zagonel, David W. Markby, Suvajit Sen, A-L Cheng, Robin Katie Kelley, Anthony B. El-Khoueiry, Baek-Yeol Ryoo, Tim Meyer, M Bitzer, JF Blanc, Stephen L. Chan
Publikováno v:
Zeitschrift für Gastroenterologie.
Autor:
Vincenzo Dadduzio, David W. Markby, Joong-Won Park, Suvajit Sen, Thomas Yau, Ghassan K. Abou-Alfa, Lorenza Rimassa, Anthony B. El-Khoueiry, Ann-Lii Cheng, Stephen L. Chan, Rajesh Kaldate, Jean-Frédéric Blanc, Baek-Yeol Ryoo, Robin Kate Kelley, Tim Meyer
Publikováno v:
Journal of Clinical Oncology. 37:423-423
423 Background: AFP response, defined as a decrease in serum levels of the tumor marker AFP after therapy, may be associated with improved survival of patients (pts) with HCC treated with locoregional or systemic therapy, and high baseline AFP levels